CytomX Therapeutics, Inc. Promotes Henry Lowman, Ph.D., to Chief Scientific Officer
10/6/2011 9:50:33 AM
SAN FRANCISCO--(BUSINESS WIRE)--CytomX Therapeutics, a biotechnology company focused on the development of proteolytically-activated antibodies, today announced the promotion of Henry Lowman, Ph.D., to chief scientific officer. In this position, Dr. Lowman will lead research and development activities to advance the company’s Probody™ candidates through optimization, pre-clinical and early clinical development.
comments powered by